1. Persistent Use of Evidence-Based Pharmacotherapy in Heart Failure Is Associated With Improved Outcomes
by Gunnar H. Gislason, Jeppe N. Rasmussen, Steen Z. Abildstrom, Tina Ken Schramm, Morten Lock Hansen, Pernille Buch, Rikke Sørensen, Fredrik Folke, Niels Gadsbøll, Søren Rasmussen, Lars Køber, Mette Madsen, and Christian Torp-Pedersen
Circulation
Volume 116(7):
August 14, 2007
Copyright © American Heart Association, Inc. All rights reserved.

2. Figure 1. Patients who survived first HF hospitalization and claimed a prescription of RASi, β-blockers, or spironolactone within 90 days or statin within 180 days from discharge.
Figure 1. Patients who survived first HF hospitalization and claimed a prescription of RASi, β-blockers, or spironolactone within 90 days or statin within 180 days from discharge.
Gunnar H. Gislason et al. Circulation. 2007;116:
Copyright © American Heart Association, Inc. All rights reserved.

3. Figure 2. Cumulative frequency of patients who survived first HF hospitalization and claimed at least 1 prescription of β-blocker, RASi, spironolactone, or statin within the first year after discharge (censored for death).
Figure 2. Cumulative frequency of patients who survived first HF hospitalization and claimed at least 1 prescription of β-blocker, RASi, spironolactone, or statin within the first year after discharge (censored for death).
Gunnar H. Gislason et al. Circulation. 2007;116:
Copyright © American Heart Association, Inc. All rights reserved.

4. Figure 3. Long-term persistence with RASi, β-blocker, spironolactone, or statin in patients with HF: the proportion of patients alive who were on treatment on each day.
Figure 3. Long-term persistence with RASi, β-blocker, spironolactone, or statin in patients with HF: the proportion of patients alive who were on treatment on each day.
Gunnar H. Gislason et al. Circulation. 2007;116:
Copyright © American Heart Association, Inc. All rights reserved.